Safety and short-term efficacy of mirabegron in children with valve bladder: a pilot study
link.springer.com shows its articles on its own site.
Read the article on link.springer.com ↗Article · Dec 2021 · 1 min read
In brief
In brief
Pilot study evaluating mirabegron therapy in 22 children with valve bladder following posterior urethral valve treatment. Three-month treatment demonstrated significant improvements in voiding frequency, incontinence episodes, urodynamic parameters, and hydronephrosis grade without significant adverse effects.
Written by the GCMD Library team from the article.
Abstract
Aims
This pilot study aims to assess the short-term efficacy and safety of mirabegron in valve bladder, an important cause of persistent hydronephrosis after successful treatment of posterior urethral valves (PUV).
Methods
Twenty-two patients with early valve bladder (no residual PUV; persistent hydronephrosis, wetting and urodynamic evidence of detrusor overactivity) were included. Three subjective parameters: frequency, wetting episodes; patient perception of bladder condition score (PPBC) and four objective parameters: uroflow index (UI = Qave/Qmax), voided volume (VV = voided volume/ expected bladder capacity), maximum filling pressure (P det-max) and society of fetal urology (SFU) hydronephrosis grading were analysed pre- and post-3-month treatment with mirabegron (0.5–1 mg/kg/day). All patients were observed for heart rate, BP, ECG changes during therapy.
Results
There was significant reduction (p = 0.001) in mean frequency (pre 15; post 10), wetting episodes (pre 5; post 2) and PPBC (pre 4; post 3). There was significant improvement (p = 0.01) in mean UI (pre 0.3; post 0.5), VV (pre 0.54; post 0.72), Pdet-max (pre 42; post 25) and hydronephrosis grade (pre 3.5; post 2.2). There were no significant side effects.
Conclusion
This pilot study establishes short-term efficacy and safety of mirabegron in valve bladder with overactivity. Further larger long-term studies are warranted.